NCT02199860已完成1 期
A Double-blind (at Each Dose Level), Randomised, Placebo-controlled, Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Two Spray-dried Formulations of BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 63
- 主要终点
- Change in lung function measurement specific conductance (SGaw)
研究概览
简要总结
The purpose of the present study was to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single inhalation administration of rising doses of spray-dried powder in healthy male and female volunteers. According to the original protocol, the primary objective was to investigate the safety and tolerability of single doses of a new spray-dried inhalation formulation of BIBN 4096 BS (SD I). Following implementation of Amendment 2, this objective was extended to the second spray-dried inhalation formulation SD II with and without concomitant administration of lactose
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects could be included in the study if they met the following criteria:
- •Healthy male or female volunteers
- •Written informed consent in accordance with Good Clinical Practice (GCP) and the local legislation prior to admission to the study
- •Age 21 - 50 years
- •Body mass index (BMI): 18.5 - 29.9 kg/m2
排除标准
- •Subjects were not allowed to participate if any of the following applied:
- •Any finding of the medical examination (including blood pressure, pulse rate, Respiratory rate, body temperature and ECG) deviating from normal and of clinical relevance
- •Raw > 3 cm H2O • s • L-1 or FEV1 <80% of predicted
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Diseases of the central nervous system, psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts,
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which was deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than 10 half-lives of the respective drug before enrolment in the study
- •Use of any drugs which might influence the results of the trial (within 1 week prior to administration of investigational drug or during the trial)
- •Participation in another trial with an investigational drug (within 2 months prior to drug administration or during the trial)
- •Smoker (>10 cigarettes/day or >3 cigars/day or >3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (>60 gram/day)
- •Drug abuse
- •Blood donation (≥100 mL within 4 weeks prior to administration of investigational drug or during the trial)
- •Excessive physical activities (within the last week before the study)
- •Any laboratory value outside the reference range and of clinical relevance
- •For female subjects:
- •Pregnancy
- •Positive pregnancy test
- •No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device
- •Inability to maintain this adequate contraception during the whole study period,
- •Lactation period
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
SD I - single rising doses
Experimental
干预措施: SD I (Drug)
SD II - single rising doses
Experimental
干预措施: SD II (Drug)
SD II - single rising doses + Placebo
Experimental
干预措施: SD II (Drug)
SD II - single rising doses + Placebo
Experimental
干预措施: Placebo (Drug)
结局指标
主要结局
Change in lung function measurement specific conductance (SGaw)
时间窗: up to 5 hours after drug administration
Number of patients with adverse events
时间窗: up to 25 days
Assessment of tolerability on a 4-point scale
时间窗: 8 days after drug administration
Change in lunf function measurement forced expiratory volume in 1 second (FEV1)
时间窗: up to 5 hours after drug administration
Change in lung function measurements airway resistance (Raw)
时间窗: up to 5 hours after drug administration
次要结局
- tmax (Time from dosing to the maximum concentration of the analyte in plasma)(up to 48 hours after drug administration)
- λz (Terminal rate constant in plasma)(up to 48 hours after drug administration)
- Cmax (Maximum measured concentration of the analyte in plasma)(up to 48 hours after drug administration)
- AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 48 hours after drug administration)
- t½ (Terminal half-life of the analyte in plasma)(up to 48 hours after drug administration)
- MRTih (Mean residence time of the analyte in the body after inhalation)(up to 48 hours after drug administration)
- AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)(up to 48 hours after drug administration)
- CL/F (Apparent clearance of the analyte in plasma following extravascular administration)(up to 48 hours after drug administration)
- Vz/F (Apparent volume of distribution of the analyte during the terminal phase)(up to 48 hours after drug administration)
研究者
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194335Boehringer Ingelheim32
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194777Boehringer Ingelheim48
已完成
1 期
Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194322Boehringer Ingelheim38
已完成
1 期
Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02194348Boehringer Ingelheim12
已完成
1 期
Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female VolunteersHealthyNCT02198326Boehringer Ingelheim32